PROGRESS *in* GROWTH FACTOR RESEARCH

Associate Editors

Andrew Baird, PRIZM Pharmaceuticals, 11035 Roselle Street, San Diego, CA 92121, USA

Mike Dexter, Paterson Laboratories, Christie Hospital, Holt Radium Institute, Manchester M20 9BX, UK

Bengt Westermark, Department of Pathology, University Hospital, 75185 Uppsala, Sweden

International Editorial Board

D Barritault, Paris, France
K Brown, Cambridge, UK
D Crowther, Manchester, UK
M Czech, Massachusetts, USA
A Dunn, Melbourne, Australia
C-H Heldin, Uppsala, Sweden
T Honjo, Kyoto, Japan
C Hopkins, London, UK
T Kishimoto, Osaka, Japan
F Lee, California, USA
C Marshall, London, UK
W Moolenaar, Amsterdam, Holland
J Pledger, Tennessee, USA
A Roberts, Maryland, USA
R Ross, Washington, USA
J J Van Wyk, North Carolina, USA

Progress in Growth Factor Research is published as 1 volume of 4 issues per year (March, June, September, December)

This journal is to be re-launched in 1996 as *Cytokine and Growth Factor Reviews*. **Annual Institutional Subscription Rates** for this journal are: North, Central and South America, US $ 334.00, Rest of World £210.00. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

Subscription enquiries from customers in North America should be sent to Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA and for the remainder of the world to: Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK.

Second class postage paid at NEWARK NJ. *Progress in Growth Factor Research* (ISSN 0955-2235) is published 4 issues per year in March, June, September and December, by Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, U.K. The annual subscription in the U.S.A. is $334.00. *Progress in Growth Factor Research* is distributed by Mercury Airfreight International Ltd. Postmaster send address corrections to *Progress in Growth Factor Research*, c/o Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, U.S.A.

Copyright © 1996 Elsevier Science Ltd. All rights reserved.

PUBLISHING/ADVERTISING OFFICES

Elsevier Science Ltd
The Boulevard
Langford Lane
Kidlington
Oxford OX5 1GB
UK

Elsevier Science Inc.
660 White Plains Road
Tarrytown, NY 10591-5153
USA

PROGRESS *in* GROWTH FACTOR RESEARCH

Associate Editors

Andrew Baird, PRIZM Pharmaceuticals, 11035 Roselle Street, San Diego, CA 92121, USA

Mike Dexter, Paterson Laboratories, Christie Hospital, Holt Radium Institute, Manchester M20 9BX, UK

Bengt Westermark, Department of Pathology, University Hospital, 75185 Uppsala, Sweden

International Editorial Board

D Barritault, Paris, France
K Brown, Cambridge, UK
D Crowther, Manchester, UK
M Czech, Massachusetts, USA
A Dunn, Melbourne, Australia
C-H Heldin, Uppsala, Sweden
T Honjo, Kyoto, Japan
C Hopkins, London, UK
T Kishimoto, Osaka, Japan
F Lee, California, USA
C Marshall, London, UK
W Moolenaar, Amsterdam, Holland
J Pledger, Tennessee, USA
A Roberts, Maryland, USA
R Ross, Washington, USA
J J Van Wyk, North Carolina, USA

Progress in Growth Factor Research is published as 1 volume of 4 issues per year (March, June, September, December)

This journal is to be re-launched in 1996 as *Cytokine and Growth Factor Reviews*. **Annual Institutional Subscription Rates** for this journal are: North, Central and South America, US $ 334.00, Rest of World £210.00. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

Subscription enquiries from customers in North America should be sent to Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA and for the remainder of the world to: Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK.

Second class postage paid at NEWARK NJ. *Progress in Growth Factor Research* (ISSN 0955-2235) is published 4 issues per year in March, June, September and December, by Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, U.K. The annual subscription in the U.S.A. is $334.00. *Progress in Growth Factor Research* is distributed by Mercury Airfreight International Ltd. Postmaster send address corrections to *Progress in Growth Factor Research*, c/o Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, U.S.A.

Copyright © 1996 Elsevier Science Ltd. All rights reserved.

PUBLISHING/ADVERTISING OFFICES

Elsevier Science Ltd
The Boulevard
Langford Lane
Kidlington
Oxford OX5 1GB
UK

Elsevier Science Inc.
660 White Plains Road
Tarrytown, NY 10591-5153
USA

CONTENTS

Volume 6, Number 1

The Role of Growth Factors in Preimplantation Development
P. L. KAYE and M. B. HARVEY 1

Biochemical and Mitogenic Properties of the Heparin-binding Growth Factor HARP
K. LAAROUBI, F. VACHEROT, J. DELBÉ, D. CARUELLE, D. BARRITAULT and J. COURTY 25

The Role of Fibroblast Growth Factor-2 (FGF-2) in Hematopoiesis
M. ALLOUCHE and A. BIKFALVI 35

Bibliographic Update 49

Volume 6, Numbers 2–4
Special Issue: Proceedings of the Third International Symposium on IGF Binding Proteins

Preface
Proceedings of the Third International Symposium on IGF Binding Proteins
K. HALL and W. F. BLUM 77

Overview
The annals of IGF binding proteins: into the next millenium
R. L. HINTZ 79

1. Gene organization and regulation of IGFBP synthesis
Multiple proteins bind the insulin response element in the human IGFBP-1 promoter
D. R. POWELL, S. V. ALLANDER, A. O. SCHEIMANN, R. M. WASSERMAN, S. K. DURHAM and A. SUWANICHKUL 93

Multiple liver-enriched *trans*-acting factors interact with the glucocorticoid- (GRU) and cAMP- (CRU) responsive units within the h-IGFBP-1 promoter
E. NEAU, D. CHAMBÉRY, G. SCHWEIZER-GROYER, F. CADEPOND, N. JIBARD and A. GROYER 103

A novel DNA/protein complex interacts with the insulin-like growth factor binding protein-1 (IGFBP-1) insulin response sequence and is required for maximal effects of insulin and glucocorticoids on promoter function
T. UNTERMAN, D. OEHLER, H. NGYUEN, P. SENGUPTA and R. LACSON 119

Dexamethasone stimulation of rat insulin-like growth factor binding protein-1 (IGFBP-1) promoter activity involves the interaction of multiple transcription factors
D.-S. SUH, Y. ZHOU, G. T. OOI and M. M. RECHLER 131

Characterisation of the rat acid-labile subunit gene
P. J. D. DELHANTY and R. C. BAXTER 141

Structure and regulation of the ALS gene
G. T. OOI, F. J. COHEN, S. HSIEH, D. SETO, M. M. RECHLER and Y. R. BOISCLAIR 151

Conservation of IGFBP structure during evolution: cloning of chicken insulin like-growth factor binding protein-5
S. V. ALLANDER, E. EHRENBORG, H. LUTHMAN and D. R. POWELL 159

Expression, effects, and fate of IGFBP-5 are different in normal and malignant osteoblastic cells
CH. SCHMID, I. SCHLÄPFER, M. A. GOSTELI-PETER, E. R. FROESCH and J. ZAPF 167

Cellular localization and hormonal regulation of biosynthesis of insulin-like growth factor binding proteins and of the acid-labile subunit within rat liver
J.-G. SCHARF, G. RAMADORI, T. BRAULKE and H. HARTMANN 175

Cytokines regulate IGF binding proteins in the CNS
T. L. WOOD, S. L. O'DONNELL and S. W. LEVISON 181

Periconceptual undernutrition resets plasma IGFBP levels and alters the the response of IGFBP-1, IGFBP-3 and IGF-1 to subsequent maternal undernutrition in fetal sheep
B. W. GALLAHER, B. H. BREIER, J. E. HARDING and P. D. GLUCKMAN 189

Differential secretory polarity of IGFBP-6 vs. IGFBP-2 and IGFBP-4 in human intestinal epithelial cells: is it a way of modulating IGF-II bioavailability towards the IGF-responsive basolateral surface?
G. J. POMMIER, M. M. REMACLE-BONNET, S. G. TRIPIER and F. L. GARROUSTE 197

2. Structure–function relationships

A 3-dimensional model for the insulin-like growth factor binding proteins (IGFBPs); supporting evidence using the structural determinants of the IGF binding site on IGFBP-3
E. M. SPENCER and K. CHAN 209

Modulation of human IGF binding protein-3 activity by structural modification
R. C. BAXTER and S. M. FIRTH 215

The role of glycosylation in the action of IGFBP-3
S. M. FIRTH and R. C. BAXTER 223

Functions and regulation of the acid-labile subunit of the 150 K complex
A. BARRECA, P. PONZANI, A. ARVIGO, A. VOCI, G. GIORDANO and F. MINUTO 231

Formation of 150-kDa binary complexes of insulin-like growth factor binding protein-3 and the acid-labile subunit *in vitro* and *in vivo*
C. Y. LEE and M. M. RECHLER 241

3. IGFBP proteases

Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases
J. L. FOWLKES, K. M. THRAILKILL, D. M. SERRA, K. SUZUKI and H. NAGASE 255

Proteolysis of IGFBPs by cathepsin D *in vitro* and in cathepsin D-deficient mice
T. BRAULKE, M. CLAUSSEN, P. SAFTIG, M. WENDLAND, K. NEIFER, B. SCHMIDT, J. ZAPF, K. VON FIGURA and C. PETERS 265

Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth
R. RAJAH, L. KATZ, S. NUNN, P. SOLBERG, T. BEERS and P. COHEN 273

Serum proteolysis of IGFBP-3
P. BANG 285

Tissue IGFBP-3 proteolysis: contrasting pathophysiology to that in the circulation
S. C. C. HUGHES, S. XU, J. FERNIHOUGH, A. HAMPTON, H. D. MASON, S. FRANKS, J.VAN DER STAPPEN, M. J. DONNELLY and J. M. P. HOLLY 293

Insulin-like growth factor binding protein proteolysis in bone cell models
C. A. CONOVER 301

A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGF is a cell growth inhibitor
C. LALOU, C. LASSARRE and M. BINOUX 311

4. Interaction with cell membranes and matrix

Cell migration: interactions among integrins, IGFs and IGFBPs
J. I. JONES, M. E. DOERR and D. R. CLEMMONS 319

Cell membrane association of insulin-like growth factor binding protein-2 (IGFBP-2) in the rat brain olfactory bulb
V. C. RUSSO, L. A. BACH and G. A. WERTHER 329

Comparison studies of IGFBP-5 binding to osteoblasts and osteoblast-derived extracellular matrix
D. L. ANDRESS 337

5. IGFBPs as modulators of IGF action

Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey
S. ADAMS, J. MOORE, S. CHU, C. BAGI, L. DELEON, C. LIU, D. SCHMIDT and A. SOMMER 347

Role of insulin-like growth factor binding proteins in the control of IGF actions
D. R. CLEMMONS, W. H. BUSBY, T. ARAI, T. J. NAM, J. B. CLARKE, J. I. JONES and D. K. ANKRAPP 357

Further characterisation of an IGF-I enhancing antibody: actions on IGF-I-induced hypoglycaemia and interaction with the analogue LR^3IGF-I
J. M. PELL, H. C. FLICK-SMITH, S. DYE and R. A. HILL 367

Co-administration of IGF-binding protein-3 differentially inhibits the IGF-I-induced total body and organ growth of Snell dwarf mice
S. VAN BUUL-OFFERS, R. REIJNEN-GRESNIGT, R. BLOEMEN, C. HOOGERBRUGGE and J. L. VAN DEN BRANDE 377

In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness
P. E. WALTON, F. R. DUNSHEA and F. J. BALLARD 385

Circulating and ovarian IGF binding proteins: potential roles in normo-ovulatory cycles and in polycystic ovarian syndrome
L. C. GIUDICE, H. J. H. M. VAN DESSEL, N. A. CATALDO, Y. A. CHANDRASEKHER, O. W. S. YAP and B. C. J. M. FAUSER 397

Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis?
E. TONNER, L. QUARRIE, M. TRAVERS, M. BARBER, A. LOGAN, C. WILDE and D. FLINT 409

6. Transgenic and gene knockout models

Human insulin-like growth factor binding protein-1 (hIGFBP-1) transgenic mice: insights into hIGFBP-1 regulation and actions
A. J. D'ERCOLE, P. YE and Z. DAI 417

Phenotypic manifestations of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 overexpression in transgenic mice
L. J. MURPHY, K. RAJKUMAR and P. MOLNAR 425

Insulin-like growth factor-I and insulin-like growth factor binding protein-3 inhibit involution of the mammary gland following lactation: studies in transgenic mice
D. LEROITH, S. NEUENSCHWANDER, T. L. WOOD, L. HENNINGHAUSEN 433

Genetic ablation of IGFBP-2 suggests functional redundancy in the IGFBP family
J. E. PINTAR, A. SCHULLER, J. A. CERRO, M. CZICK, A. GREWAL and B. GREEN 437

7. Clinical studies

Regulation of IGFBP-1 in humans
KERSTIN BRISMAR, AGNETA HILDING AND BJÖRN LINDGREN 449

Clinical information on serum IGFBP-3 levels and IGFBP-3 proteolytic activity in childhood
YUKIHIRO HASEGAWA, TOMONOBU HASEGAWA, KATSURA FUJII, HIDEKO KONII, MAKOTO ANZO, TAIJI ASO, SHINOBU KOTOH and YUTAKA TSUCHIYA 457

Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: Implications for bone loss with aging
S. MOHAN, J. R. FARLEY and D. J. BAYLINK 465

Developmental regulation of circulating insulin-like growth factor-binding proteins in normal pregnancies and in pre-eclampsia
MOIRA S. LEWITT, FERGUS P. SCOTT, NICOLE M. CLARKE and ROBERT C. BAXTER 475

Insulin-like growth factors (IGF) and IGF binding proteins in children with chronic renal failure
BURKHARD TÖNSHOFF, WERNER F. BLUM and OTTO MEHLS 481

8. IGFBPs in tumors

Regulation of IGFBP-3 expression in breast cancer cells and uterus by estra-diol and antiestrogens: correlation with effects on proliferation: A review
HUYNH HUNG and MICHAEL POLLAK 495

Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells
YOUNGMAN OH, ZORAN GUCEV, LILLY NG, HERMANN L. MÜLLER and RON G. ROSENFELD 503

Components of the IGF system mediate the opposing effects of Tamoxifen on endometrial and breast cancer cell growth
MICHAEL KARAS, DITA KLEINMAN, MICHAEL DANILENKO, CHARLES T. ROBERTS JR, DEREK I.EROITH, JOSEPH LEVY and YOAV SHARONI 513